Nuclear Medicine and Biology
Volume 37, Issue 2 , Pages 143-148, February 2010

A 1-methyl-4-piperidinyl cytectrene carboxylate labeled by the technetium 99m, a radiotracer for rat brain acetylcholinesterase activity

Radiopharmaceutical Unit, National Centre of Sciences and Nuclear Technologies, Sidi Thabet 2020, Tunisia

Received 16 July 2009; received in revised form 8 September 2009; accepted 2 October 2009. published online 06 November 2009.

Abstract 

Alzheimer's disease (AD) is a degenerative neurological disorder that causes progressive and irreversible loss of connections between brain cells and loss of mental functions.

Clinical and postmortem studies show that the biochemical changes in brains of AD patients include decrease in acetylcholinesterase (AChE) activity.

Our aim was to study AChE activity using piperidinyl ester labelled with technetium-99m. In vivo and in vitro studies demonstrated that labelled piperidinyl ester was a substrate for AChE. The hydrolytic rate of this substrate was measured and the specificity was evaluated using the inhibitor BW284c51.

The rhenium analogues of the technetium-labelled substrate were used to determine the affinity constant (Km) and the maximum reaction velocity (Vmax) because of the high specific activity of technetium. The high hydrolytic rate and high specificity of the substrate for AChE make it suitable as an in vivo radiotracer for studying AChE activity in the brain.

Keywords: 1-Methyl-4-piperidinyl cytectrene carboxylate, Technetium 99m, Acetylcholinesterase activity

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0969-8051(09)00240-6

doi:10.1016/j.nucmedbio.2009.10.002

Nuclear Medicine and Biology
Volume 37, Issue 2 , Pages 143-148, February 2010